ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

RNLX Renalytix PLC

0,44
0,0044 (1,01%)
Vor Marktöffnung
Zuletzt aktualisiert: 14:14:49
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Renalytix PLC RNLX NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
0,0044 1,01% 0,44 14:14:49
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,4356
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
15.5.202416:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15.5.202415:23EDGAR2Form 8-K - Current report
15.5.202413:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15.5.202413:00EDGAR2Form 8-K - Current report
15.5.202413:00GLOBERenalytix Reports Financial Results for Third Quarter of..
09.5.202413:00GLOBERenalytix to Report Financial Results for Third Quarter..
08.4.202413:00GLOBERenalytix Announces Financing with Expected Size of up to $4..
14.3.202412:00GLOBEKidneyIntelX™ included in Final KDIGO 2024 Clinical..
15.2.202413:00GLOBERenalytix Reports Financial Results for Second Quarter of..
15.2.202413:00EDGAR2Form 8-K - Current report
14.2.202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.2.202415:00GLOBERenalytix to Participate in the BTIG MedTech, Digital..
17.1.202413:15EDGAR2Form 8-K - Current report
10.1.202413:15EDGAR2Form 8-K - Current report
10.1.202413:00GLOBENew published data demonstrates KidneyIntelX™ has broad..
29.12.202322:02EDGAR2Form 8-K - Current report
17.11.202322:01EDGAR2Form ARS - Annual Report to Security Holders
14.11.202313:00GLOBERenalytix Reports Financial Results for First Quarter of..
07.11.202313:00GLOBERenalytix to Report Financial Results for First Quarter..
03.11.202321:04EDGAR2Form PRE 14A - Other preliminary proxy statements
24.10.202314:00EDGAR2Form 8-K - Current report
06.10.202313:00GLOBEUS Patent Office Allows Patent Claims for Intellectual..
28.9.202313:00GLOBERenalytix Reports Full Year Fiscal 2023 Results
25.9.202313:00GLOBERenalytix to Report Financial Results for Fourth Quarter and..
08.9.202322:04EDGAR2Form 8-K - Current report
07.9.202313:00GLOBERenalytix Appoints Senior Executive Howard Doran as Chief..
03.8.202313:00GLOBERenalytix Clinical Advisory Board Formed to Support..
21.7.202313:00GLOBERenalytix Announces Middle East Distribution Agreement with..
07.7.202313:00GLOBELate-Breaking KidneyIntelX Evidence Released at 83rd..
03.7.202313:00GLOBERenalytix Appoints Financial Executive Catherine Coste to..
30.6.202300:58DJNRenalytix Gets FDA De Novo Marketing Authorization for..
30.6.202300:01GLOBEFDA Grants De Novo Marketing Authorization for..
15.6.202313:00GLOBEKidneyIntelX™ Clinical Decision Impact / Validation and..
09.6.202313:00GLOBERenalytix Reports Financial Results for Third Quarter of..
05.6.202313:00GLOBERenalytix to Report Third Quarter Fiscal Year 2023 Financial..
25.5.202313:00GLOBERenalytix selects EVERSANA® to expand commercialization of..

Kürzlich von Ihnen besucht